Please assess the completion status of the following clinical trial:

Trial Title: B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with CFS~* age 18-66 years~* informed consent~Exclusion Criteria:~* patients with fatigue, not fulfilling criteria for CFS~* pregnancy or lactation~* previous malignant disease except basal cell carcinoma of skin and cervical carcinoma in situ~* previous major immunological disease, except autoimmune diseases such as diabetes mellitus or thyroiditis~* previous long-term use of immunosuppressive drugs, except steroids e.g. in obstructive lunge disease~* endogenous depression~* lack of ability to comply by the protocol~* multi-allergy with risk of serious drug reaction~* reduced renal function (creatinin \> 1.5 x UNL)~* reduced liver function (bilirubin or transaminases \> 1.5 x UNL)~* HIV positivity~* evidence of clinically significant infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 66 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab (Type: EXPERIMENTAL): Rituximab induction using two infusions (500mg/m2, max 1000 mg) two weeks apart, followed by maintenance Rituximab infusions (500 mg/m2, max 1000 mg) after 3, 6, 10 and 15 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).